Evidence map›Paper›PMID 40468658›Full record

ArticleJournal of microbiology (Seoul, Korea)2025

Protocol for the generation and purification of minicells from Lactiplantibacillus plantarum.

Hyemin Kang, Donghyun Kim, Juhyun Kim

Abstract read
In one paragraph

Article in Journal of microbiology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A Safe and Versatile Minicell Platform Derived fromJournal of microbiology and biotechnology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hyemin KangSchool of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Republic of Korea.
Donghyun KimDepartment of Microbiology and Immunology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
Juhyun KimSchool of Life Sciences, BK21 FOUR KNU Creative BioResearch Group, Kyungpook National University, Daegu 41566, Republic of Korea.

Funding

Agency for Defense DevelopmentDefense Acquisition Program Administration 915079201Korea Health Industry Development InstituteMinistry of Health and Welfare RS-2023-00304637Ministry of Science and ICTNational Research Foundation of Korea 2022R1A2C1006157National Research Foundation of Korea 2022R1A4A1025913
6 · The paper itself

Abstract

Minicells, which are anucleate cells generated by irregular cell division, are emerging as promising drug delivery systems owing to advances in synthetic biology. However, their development is largely limited to a few model bacteria, highlighting the need to explore minicell platforms in alternative hosts. Lactiplantibacillus plantarum (L. plantarum), a probiotic bacterium classified as Generally Recognized as Safe, is an ideal candidate for such exploration. Minicell-producing L. plantarum was engineered by deleting the putative minD gene via plasmid-mediated homologous recombination, which inactivates cell division to form spherical minicells. Anucleate cells were isolated through differential centrifugation and filtration, followed by additional drug treatment to completely eliminate progenitor cells. Microscopy and flow cytometry analyses of the purified sample confirmed the absence of progenitor cells by DAPI staining. This protocol effectively produces bacterial minicells from L. plantarum for use in various biotechnological applications, including therapeutic agent delivery.

Indexed as

Lactiplantibacillus plantarumBacterial ProteinsCell DivisionDrug Delivery SystemsFlow CytometryHomologous RecombinationPlasmidsProbioticsBacterial ProteinsL. plantarumMinDminicells

Identifiers

PMID40468658
PMCPMC13576992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.